Abstract
OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have